News dal mondo
07
Apr
Trump tariff order pushes onshore drug manufacturing longer term: analysts
Leerink Partners analysts see no near-term material changes to U.S. onshoring narrative, given Trump’s executive order late last week on pharmaceutical imports....[PharmaManufacturing]
23
Top Drugs at Risk of Supply Shortages
Nearly half of 100 vulnerable medicines have at least one key starting material sourced exclusively...
Regulatory considerations for pharmaceutical excipient selection
The article discusses the role and importance of excipients in medicines, focusing on regulatory aspects...
21
TGA clarifies therapeutic goods are unaffected by chemical production and import ban
TGA has clarified the impact of Australia’s industrial chemicals standards on medicines, medical...
20
US FDA Draft Guidance on Establishing Impurity Specifications for Antibiotics
FDA issued the draft guidance for industry, Establishing Impurity Specifications for Antibiotics. This...
le ultime news
11 Mar
EMA outlines methods for evaluating supply chain vulnerabilities
09 Mar
US FDA drafts guidance on best practices for responding to inspection observations
Intelligenza Artificiale e salute: le agenzie regolatorie al centro della rivoluzione farmaceutica
06 Mar
Testo unico Legislazione Farmaceutica,: assegnato alla X Commissione Senato
04 Mar
ECHA’s Risk Assessment Committee adopts its opinion on PFAS restriction proposal
27 Feb
US FDA Announces the 2026 QMM Prototype Assessment Protocol Evaluation Program
Quantum computing nelle life sciences: a Milano un convegno per l’industria farmaceutica
24 Feb
Industry clamors for clearer guidance on transition to ICH M4Q(R2)
<<<4 5 6>>>
